Adage Capital Partners
AVEO

Adage Capital Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Adage Capital Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,500,000
Closed -$7.04M – 1193
2021
Q4 		$7.04M Hold
1,500,000
– – 0.01% 778
2021
Q3 		$9.27M Buy
1,500,000
+19,000
+1% +$114K 0.02% 709
2021
Q2 		$9.76M Buy
1,481,000
+517,000
+54% +$3.56M 0.02% 701
2021
Q1 		$7.06M Buy
+964,000
New +$8.32M 0.01% 757

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Adage Capital Partners's AVEO Position: Q1 2022 in Review

Adage Capital Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2022, closing a stake of 1,500,000 shares — an estimated $7.04M sold.

Adage Capital Partners first reported a position in AVEO in Q1 2021 and held it in 4 quarters. The position peaked at $9.76M in Q2 2021. 58 funds tracked by Wall St. Rank hold AVEO as of Q1 2022.

  • Adage Capital Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Adage Capital Partners sold 1,500,000 AVEO Pharmaceuticals, Inc. shares in Q1 2022, an estimated $7.04M.
  • Adage Capital Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
  • Adage Capital Partners's AVEO Pharmaceuticals, Inc. position peaked at $9.76M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2022.

Based on Adage Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.